# Mechanisms Linking Oxidative Stress and Sarcopenia in Cardiovascular Diseases: A Scoping Review

**Authors:** Sabina Krupa-Nurcek, Tomasz Semań, Mateusz Szczupak, Jacek Kobak, Wioletta Mędrzycka-Dąbrowska, Kazimierz Widenka

PMC · DOI: 10.3390/antiox15020184 · Antioxidants · 2026-02-01

## TL;DR

This review explores how oxidative stress and muscle loss are connected in cardiovascular diseases, highlighting their shared impact on health.

## Contribution

The study identifies oxidative stress as a key link between sarcopenia and cardiovascular diseases, suggesting new therapeutic targets.

## Key findings

- Oxidative stress contributes to muscle cell damage and mitochondrial dysfunction in cardiovascular diseases.
- Reduced antioxidant capacity and elevated reactive oxygen species may accelerate muscle mass decline.
- Chronic inflammation linked to oxidative stress is associated with sarcopenia progression in these patients.

## Abstract

Oxidative stress and sarcopenia are increasingly perceived as interdependent processes that significantly affect the course of cardiovascular diseases. Excessive production of reactive oxygen species leads to muscle cell damage, mitochondrial disorders, and chronic inflammation, which promote progressive loss of muscle mass and function. Methods: The aim of the study was to analyze the mechanisms linking oxidative stress and sarcopenia in the course of cardiovascular diseases. Our scoping review initially identified 854 articles, of which 3 were ultimately included in the review (after removing duplicates (n = 118), 736 articles remained; after re-screening the articles according to the inclusion and exclusion criteria (n = 302), 434 articles remained; 196 publications lacked full text and were excluded, leaving 238 articles). Results: An examination of the available literature indicates a potential association between increased oxidative stress and the possible development of sarcopenia in individuals with cardiovascular diseases. The studies identified in this review suggest that elevated levels of reactive oxygen species, together with reduced antioxidant capacity, may contribute to muscle fiber damage, mitochondrial disturbances, and the activation of chronic inflammatory processes, which could in turn be involved in the accelerated decline of muscle mass and strength. Conclusions: These results confirm that oxidative stress is a key pathophysiological element linking both disease entities and may be an important target of therapeutic interventions.

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, CAT (catalase) [NCBI Gene 847], SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** metabolic diseases (MESH:D008659), muscle fiber damage (MESH:C563545), hypoxia (MESH:D000860), Loss of muscle mass (MESH:C536030), falls (MESH:C537863), arrhythmia (MESH:D001145), stroke (MESH:D020521), fatigue (MESH:D005221), chronic obstructive pulmonary disease (MESH:D029424), cancer (MESH:D009369), systolic and diastolic insufficiency (MESH:D000309), endothelial dysfunction (MESH:D014652), chronic kidney disease (MESH:D051436), fibrosis (MESH:D005355), Chronic inflammation (MESH:D007249), muscle damage (MESH:D009133), Sarcopenia (MESH:D055948), injury to (MESH:D014947), metabolic, inflammatory and degenerative disorders (MESH:D019636), oxidative disorders (MESH:D004194), circulatory failure (MESH:D012769), Mitochondrial dysfunction (MESH:D028361), acute coronary syndrome (MESH:D054058), muscle (MESH:D019042), muscle cell damage (MESH:D002280), infectious complications (MESH:D003141), chronic (MESH:D002908), slowing of gait (MESH:D020234), heart failure (MESH:D006333), type 2 diabetes (MESH:D003924), Heart Disease (MESH:D006331), Reduced muscle mass (MESH:D009135), mitochondrial and peroxisome dysfunctions (MESH:D018901), myocardial or vascular pathologies (MESH:D005598), Cardiovascular Diseases (MESH:D002318), heart attack (MESH:D009203), insulin resistance (MESH:D007333), Deficiency of NADPH (MESH:C563171), atherosclerosis (MESH:D050197), malnutrition (MESH:D044342)
- **Chemicals:** 4-HNE (MESH:C027576), Oxysterols (MESH:D000072376), cholesterol (MESH:D002784), phospholipids (MESH:D010743), testosterone (MESH:D013739), pentose phosphate (MESH:D010428), 7-ketocholesterol (MESH:C003001), membrane lipid (MESH:D008563), ROS (MESH:D017382), glucose (MESH:D005947), 7-beta-hydroxycholesterol (MESH:C011724), GSH (MESH:D005978), ATP (MESH:D000255), polyphenols (MESH:D059808), Lipid (MESH:D008055), amino acids (MESH:D000596), NADPH (MESH:D009249), fatty acids (MESH:D005227), GSSG (MESH:D019803), superoxide (MESH:D013481), oxisterols (-), sulfur amino acids (MESH:D000603)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938792/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938792/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938792/full.md

---
Source: https://tomesphere.com/paper/PMC12938792